Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
Biological age & clocks
Research brief

Plasma proteins partly link biological aging to MASLD risk in a UK Biobank cohort

In 52,131 UK Biobank participants followed a median 13.60 years, all four biological aging indicators were linked to incident MASLD, and plasma proteins partly mediated this association. [1]

Automatic summary · not editorially reviewed

The key findings

  1. The study analyzed 2,911 plasma proteins in 52,131 UK Biobank participants and linked all four biological aging indicators to MASLD incidence. [1]

  2. Over a median 13.60 years, 762 participants developed MASLD; proteins mediated 0.5 to 50.7% of the risk, with five proteins shared across all indicators. [1]

  3. Enrichment analyses indicated a multi-organ protein origin, mainly lung, adipose tissue and arteries, with immune-inflammatory pathways dominating. [1]

The source at a glance

Study type / format
Prospective cohort study (abstract).
Population / context
52,131 UK Biobank participants, of whom 762 developed MASLD during follow-up.
Summary based on
Study abstract
Original publication
October 7, 2026

Aging indicators and MASLD in 52,131 UK Biobank adults

The study asked how biological aging relates to new metabolic dysfunction-associated steatotic liver disease (MASLD) and which plasma proteins might be involved. It used four biological aging indicators: telomere length, frailty index, Klemera-Doubal method biological age and phenotypic age. It analyzed 2,911 plasma proteins in 52,131 UK Biobank participants. All four indicators were significantly linked to MASLD incidence. This is an association in a cohort, not proof that aging causes MASLD.

Supporting source [1]

Proteins mediating the aging–MASLD link over 13.60 years

During a median follow-up of 13.60 years, 762 participants developed MASLD. The researchers identified distinct protein patterns for the four aging indicators. Multiple proteins significantly mediated the corresponding association, explaining 0.5 to 50.7% of the risk. In total, 769 unique mediators were found, with a core set of five proteins (AXL, CCL19, CPM, REN and TNFRSF11B) shared across all four indicators. Mediation here is statistical, so it does not establish a causal chain.

Supporting source [1]

Multi-organ protein origin and immune-inflammatory pathways

Enrichment analyses pointed to a multi-organ origin of the proteins, mainly lung, adipose tissue and arteries, with immune-inflammatory pathways dominating. The authors conclude that plasma proteins partly mediate the higher MASLD risk associated with biological aging and suggest these proteins as biomarkers for early risk stratification and possible therapeutic targets. These are proposed implications from an abstract, not validated clinical tools. The abstract reports no full-text review, and the observational design cannot show causation.

Supporting source [1]

How to interpret this

Abstract only; the full text was not reviewed. This is an observational cohort, so the links and mediation are associations, not causes. The biomarker and therapeutic-target suggestions are proposals, not validated tools.

Based on the study abstract; the full paper, tables and supplementary data were not reviewed.

Source & supporting passages

[1]
Plasma proteomic signatures of biological aging and metabolic dysfunction-associated steatotic liver disease risk: a prospective cohort study.

Cao TR, Wu LJ, Yang XH, Fan NF, Ding J, Gong M, Feng XM, Li YH, Yan YX. · europepmc.org · October 7, 2026

Read the quoted passagesIn the language of the original source
  1. Finding 1 ↑

    2911 plasma proteins, and incident MASLD among
  2. Finding 2 ↑

    explaining 0.5 to 50.7% of the risk
  3. Finding 3 ↑

    predominantly lung, adipose tissue, and arteries

AI-assisted summary with linked source passages. No independent editorial or clinical review.

Our editorial method

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…